Search
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicitIt is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Prinomastat
go.drugbank.com/drugs/DB05100InvestigationalAs a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.
Thyrotropin alfa
go.drugbank.com/drugs/DB00024ApprovedInvestigationalVet approvedIt is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues … Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAnti-SARS-CoV-2 REGN-COV2
go.drugbank.com/drugs/DB15691Investigationalincluding contacts of an infected individual. … Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalAcromegaly is a life-threatening disease requiring life-long management. … [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SANDOSTATİN 0,1 MG/ML SC/IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİGadoquatrane
go.drugbank.com/drugs/DB33282ApprovedGadoquatrane is a macrocyclic gadolinium-based contrast agent used to enhance magnetic resonance imaging. … [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity
MDX-1379
go.drugbank.com/drugs/DB05329InvestigationalMDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.